[Form 4] Wave Life Sciences Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Gregory L. Verdine, a director of Wave Life Sciences Ltd. (WVE), reported a sale of 10,000 ordinary shares on 08/22/2025 at a price of $10 per share, executed under a Rule 10b5-1 trading plan adopted March 13, 2025. After the reported disposition, Mr. Verdine beneficially owned 285,217 ordinary shares. The Form 4 was signed by Mr. Verdine on 08/26/2025 and indicates the transaction was effected pursuant to the specified 10b5-1 plan.

Insights

Securities Analyst

TL;DR: Routine insider sale under a 10b5-1 plan; notable for transparency but not clearly material to valuation.

The filing documents a planned sale of 10,000 ordinary shares by Director Gregory Verdine at $10 per share under a Rule 10b5-1 plan adopted March 13, 2025. Such plans are commonly used to avoid insider trading compliance issues and to provide pre-arranged liquidity. The remaining beneficial ownership of 285,217 shares is disclosed, which helps quantify his stake but does not by itself reveal intent about company fundamentals. No other transactions or derivative activity are reported.

Corporate Governance Expert

TL;DR: Filing reflects compliance with insider trading rules via a documented 10b5-1 plan; governance disclosure appears complete for this event.

The Form 4 shows the director used an established Rule 10b5-1 trading plan for the sale, which supports procedural compliance and reduces concerns about opportunistic trading around nonpublic events. The report includes the directors role, transaction date, price, shares sold, and post-sale ownership, meeting disclosure expectations. No amendments or additional related-party transactions are disclosed in this filing.

Insider Trade Summary

Net Seller: 10,000 shares ($100,000)

Net Sell 1 txn

Insider Verdine Gregory L.

Role Director

Sold 10,000 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	10,000	$10.00	$100K

Holdings After Transaction: Ordinary Shares — 285,217 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verdine Gregory L.

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/22/2025		S(1)		10,000	D	$10	285,217	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.

	/s/ Gregory L. Verdine	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.